US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyntra Bio Inc

6.59

+0.05000.76%

Post-market: 6.590.00000.00%19:45 EDT

Volume:31.00K

Turnover:203.92K

Market Cap:26.66M

PE:0.15

High:6.86

Open:6.61

Low:6.38

Close:6.54

52wk High:12.60

52wk Low:4.85

Shares:4.05M

Float Shares:3.62M

Volume Ratio:0.96

T/O Rate:0.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):45.37

EPS(LYR):45.37

ROE:--

ROA:-16.96%

PB:-0.89

PE(LYR):0.15

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale

Kyntra Bio Q4 2025 net loss rises 67.97% to USD 14.6 million as revenue falls 59.25% to USD 1.28 million

Kyntra Bio Inc - Phase 2 FG-3246 Trial in Mcrpc Enrolling, Interim Analysis Expected 2H 2026

THOMSON REUTERS

Kyntra Bio Inc - Q4 EPS $-3.51

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KYNB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYNB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","market":"US","secType":"STK","nameCN":"Kyntra Bio Inc","latestPrice":6.59,"timestamp":1774641600000,"preClose":6.54,"halted":0,"volume":30996,"hourTrading":{"tag":"盘后","latestPrice":6.59,"preClose":6.59,"latestTime":"19:45 EDT","volume":10,"amount":66.0062,"timestamp":1774655135234,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0076452599388378934,"floatShares":3623701,"shares":4045445,"eps":45.371456,"marketStatus":"Market Closed","change":0.05,"latestTime":"03-27 16:00:00 EDT","open":6.61,"high":6.86,"low":6.38,"amount":203918.7944,"amplitude":0.073394,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":45.371456,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":6.54,"preHourTrading":{"tag":"盘前","latestPrice":6.62,"preClose":6.54,"latestTime":"07:50 EDT","volume":14,"amount":92.68,"timestamp":1774612231360,"change":0.08,"changeRate":0.012232,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":6.59,"preClose":6.59,"latestTime":"19:45 EDT","volume":10,"amount":66.0062,"timestamp":1774655135234,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.958791},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","floatShares":3623701,"roa":"-16.96%","roe":"--","lyrEps":45.371456,"volumeRatio":0.958791,"shares":4045445,"dividePrice":0,"high":6.86,"amplitude":0.073394,"preClose":6.54,"low":6.38,"week52Low":4.85,"pbRate":"-0.89","psRate":"4.14","week52High":12.6,"institutionHeld":0,"latestPrice":6.59,"eps":45.371456,"divideRate":0,"volume":30996,"delay":0,"ttmEps":45.371456,"open":6.61,"prevYearClose":8.78,"prevWeekClose":7.13,"prevMonthClose":6.93,"prevQuarterClose":8.78,"fiveDayClose":7.13,"twentyDayClose":6.93,"sixtyDayClose":8.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYNB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-16","symbol":"KYNB","fiscalQuarterEnding":"2025/12","expectedEps":-3.89,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"post","actualEps":-3.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYNB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYNB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1734494400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYNB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYNB","date":"2026-03-27","current":0.145246,"percent":0.351852,"low":0.128311,"twenty":0.133714,"median":0.1489,"eighty":0.163953,"high":0.18215,"avg":0.150162,"sd":0.014866,"marketCap":26466248},"quantilePoints":[{"date":"2026-01-09","current":0.17821,"twenty":0.178998,"median":0.18018,"eighty":0.181362,"marketCap":38431727},{"date":"2026-01-16","current":0.170144,"twenty":0.170369,"median":0.172958,"eighty":0.17821,"marketCap":36692186},{"date":"2026-01-23","current":0.168268,"twenty":0.168268,"median":0.171269,"eighty":0.17821,"marketCap":36287641},{"date":"2026-01-30","current":0.150259,"twenty":0.160389,"median":0.169206,"eighty":0.172958,"marketCap":32404014},{"date":"2026-02-06","current":0.140692,"twenty":0.153073,"median":0.163953,"eighty":0.171457,"marketCap":30340837},{"date":"2026-02-13","current":0.140317,"twenty":0.147445,"median":0.160201,"eighty":0.171269,"marketCap":30259928},{"date":"2026-02-20","current":0.14707,"twenty":0.146282,"median":0.158795,"eighty":0.170369,"marketCap":31716288},{"date":"2026-02-27","current":0.13075,"twenty":0.144894,"median":0.154199,"eighty":0.170144,"marketCap":28196751},{"date":"2026-03-06","current":0.129155,"twenty":0.137315,"median":0.150635,"eighty":0.168643,"marketCap":27852888},{"date":"2026-03-13","current":0.131688,"twenty":0.133714,"median":0.147445,"eighty":0.165191,"marketCap":28399023},{"date":"2026-03-20","current":0.161033,"twenty":0.133301,"median":0.147633,"eighty":0.164047,"marketCap":29541837},{"date":"2026-03-27","current":0.144268,"twenty":0.133714,"median":0.1489,"eighty":0.163953,"marketCap":26466248}],"updateTime":1774709681398},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYNB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620491310","title":"Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491310","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491310?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:25","pubTimestamp":1773692757,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale. Kyntra Bio said it completed the sale of its FibroGen China business to AstraZeneca for about USD 220 million and repaid a term loan to Morgan Stanley Tactical Value. The company said its cash runway has been extended into 2028. Kyntra Bio highlighted FG-3246, a CD46-targeting antibody-drug conjugate, and FG-3180, a PET imaging agent, with a Phase 2 monotherapy trial in metastatic castration-resistant prostate cancer enrolling and interim results expected in 2H 2026. It also said it submitted a final Phase 3 protocol to the FDA for roxadustat in anemia of lower-risk myelodysplastic syndromes, with a potential Phase 3 initiation in 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL2DcCGh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU0526926950.USD","LU0957799991.USD","LU0128525929.USD","LU0203347892.USD","LU1481600234.SGD","LU1989772923.USD","LU2089284900.SGD","LU2293690082.USD","LU1046234339.USD","LU0158827948.USD","LU1301847155.USD","LU0784385840.USD","LU0289739699.SGD","LU2324357040.USD","SG9999001176.SGD","LU0823399737.USD","LU2279689827.SGD","LU0827474353.SGD","LU0345777147.USD","LU1064927863.SGD","LU1989772840.SGD","03165","LU0889566641.SGD","SG9999001176.USD","AZN.UK","KYNB","LU0708994859.HKD","LU1119994496.HKD","LU0823416689.USD","LU0052756011.USD","SG9999013999.USD","LU1880407215.USD","LU1323610961.USD","LU0661504455.SGD","LU1880407132.USD","LU2114397693.USD","LU1989771016.USD","IE00BJT1NW94.SGD","LU1104425308.USD","IE00BFTCPJ56.SGD","LU0211326839.USD","LU1291159041.SGD","LU0499090636.EUR","LU0976567544.SGD","LU1267930813.SGD","LU0757432116.USD","LU0784384876.USD","LU0553294199.USD","LU0784383803.USD"],"gpt_icon":0},{"id":"2620949987","title":"Kyntra Bio Q4 2025 net loss rises 67.97% to USD 14.6 million as revenue falls 59.25% to USD 1.28 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620949987","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620949987?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:03","pubTimestamp":1773691392,"startTime":"0","endTime":"0","summary":"Kyntra Bio published a fourth-quarter and full-year 2025 earnings press release. Q4 total revenue from continuing operations fell 59.2% to USD 1.28 million, and net loss from continuing operations widened 68.4% to USD 14.61 million. For FY 2025, total revenue from continuing operations fell 78.3% to USD 6.44 million, while net loss from continuing operations narrowed 62% to USD 58.2 million. Cash, cash equivalents, investments, and accounts receivable totaled USD 109.4 million at Dec. 31, and the company said this is expected to fund operating plans into 2028. Kyntra said its Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer is actively enrolling with interim analysis planned for 2H 2026, and it submitted the Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes with a target to start the trial in 2H 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL62CBBq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","BK4585","LU2095319765.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4112","BK4139","LU2210149790.SGD","NDAQ","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","KYNB"],"gpt_icon":0},{"id":"2620998404","title":"Kyntra Bio Inc - Phase 2 FG-3246 Trial in Mcrpc Enrolling, Interim Analysis Expected 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620998404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620998404?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA7TCB6L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYNB","BK4139"],"gpt_icon":0},{"id":"2620499533","title":"Kyntra Bio Inc - Q4 EPS $-3.51","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499533?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA7TCB6L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/KYNB\",params:#limit:6,delay:false,,,undefined,":[]}}